Autori: A. Georgescu, N. Alexandru, E. Andrei, I. Titorencu, E. Dragan, C. Tarziu, S Ghiorghe, E. Badila, D. Bartos, D. Popov.
Editorial: J Thromb Haemost, 10(4), p.680-91, 2012.
Summary. Aims: This study aimed to (i) employ our newly designed model, the hypertensive-hypercholesterolemic hamster(HH), in order to find out whether a correlation exists between circulating microparticles (MPs), endothelial progenitor cells (EPCs) and their contribution to vascular dysfunction and (ii) to assess the effect of irbesartan treatment on
HH animals (HHI). Methods and Results: The results showed that compared with the control (C) group, HH displayed: (i) a significant increase in plasma cholesterol and triglyceride
concentration, and an augmentation of systolic and diastolic arterial blood pressure, and of heart rate; (ii) amarked elevation of MPs and a significant decrease in EPCs; (iii) structural modifications of the arterial wall correlated with altered protein
expression of MMP2, MMP9, MMP12, TIMP1, TIMP2 and collagen type I and III; (iv) a considerably altered reactivity of
the arterial wall closely correlated with MPs and EPC adherence; and (v) an inflammatory process characterized by
augmented expression of P-Selectin, E-Selectin, von Willebrand factor, tissue factor, IL-6,MCP-1 andRANTES. Additionally,the experiments showed the potential of irbesartan to correct all
altered parameters in HH and to mobilize EPCs by NO,chemokines and adhesion molecule-dependent mechanisms.
Conclusions: Hypertension associated with hypercholesterolemia is accompanied by structural modifications and
expression of pro-inflammatory molecules by the vessel wall,the alteration of vascular tone, enhanced release of MPs and reduced EPCs; the ratio between the latter two may be considered as a marker of vascular dysfunction. Irbesartan,which exhibits a pharmacological control on the levels of MPs and EPCs, has the potential to restore homeostasis of the arterial wall.
Cuvinte cheie: circulating microparticles, endothelial progenitor cells, vascular dysfunction, irbesartan